A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Oct 2017 Results of pooled analysis (n=294) describing the effectiveness of the single tablet regimen of ledipasvir/sofosbuvir using data from two prospective clinical trials (NCT02472886, NCT02480387) and four real world cohorts (German Hepatitis C-Registry,Madrid-CoRe,Veterans Health Administration,Saint Michaels), presented at the IDWeek 2017.
- 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jul 2015 New trial record